Stephanie Bounds
Psychiatric/Mental Health · Poplarville, MSNPI 1740766252
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,927 of the $8,936 with a category attached, or 66.3%. 21 manufacturers reported payments, led by AbbVie at 57.2% of the total. Reporting peaked in 2024 at $4,380 and has fallen 75.2% since, to $1,087 in 2025. Among psychiatric/mental health clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 361 payments — averaging $24.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Takeda Pharmaceuticals U.S.A., Inc.$388
- Corium, LLC$386
- Vanda Pharmaceuticals Inc.$347
- Neurocrine Biosciences, Inc.$233
- plus $1K from 15 others
What the payments were for
- Speaking & faculty fees$3,00034%
- Food & beverage$5,92766%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 144 | $5,109 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 63 | $1,158 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $388 |
| Corium, LLC | 21 | $386 |
| Vanda Pharmaceuticals Inc. | 19 | $347 |
| Neurocrine Biosciences, Inc. | 12 | $233 |
| Ironshore Pharmaceuticals Inc. | 17 | $215 |
| Otsuka America Pharmaceutical, Inc. | 10 | $190 |
| Supernus Pharmaceuticals, Inc. | 7 | $173 |
| Lundbeck LLC | 8 | $153 |
| Teva Pharmaceuticals USA, Inc. | 7 | $115 |
| Axsome Therapeutics, Inc. | 4 | $102 |
| Alkermes, Inc. | 5 | $87 |
| E.r. Squibb & Sons, L.L.C. | 4 | $67 |
| Tris Pharma Inc | 3 | $57 |
| Sunovion Pharmaceuticals Inc. | 5 | $43 |
| Johnson & Johnson | 2 | $30 |
| Indivior Inc. | 1 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| Noven Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$3,327
How this compares
$8,936 in reported general payments places this provider in the 95th percentile of 486 psychiatric/mental health providers in Mississippi.
See all psychiatric/mental health providers in Mississippi →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 29 | $268,197 |
| VraylarCariprazine Hcl | 80 | $121,188 |
| Invega SustennaPaliperidone Palmitate | 21 | $69,350 |
| CaplytaLumateperone Tosylate | 28 | $48,271 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $6,022 |
| Clozapine | 25 | $3,350 |
| Atomoxetine Hcl | 16 | $3,228 |
| Vilazodone Hcl | 20 | $2,835 |
| Quetiapine Fumarate | 184 | $2,816 |
| Haloperidol | 38 | $2,672 |
| Bupropion XlBupropion Hcl | 32 | $2,486 |
| Aripiprazole | 53 | $2,369 |
| Oxcarbazepine | 26 | $2,024 |
| Carbamazepine ErCarbamazepine | 12 | $1,867 |
| Trazodone Hcl | 196 | $1,822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $233 | $268,19729 claims |
| AbbVieVraylar | $5,109 | $121,18880 claims |
| Johnson & JohnsonInvega Sustenna | $30 | $69,35021 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,158 | $48,27128 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $388 | $6,02216 claims |
| Lilly USA, LLCOlanzapine | $21 | $1,20963 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 486 psychiatric/mental health providers in Mississippi.
Other psychiatric/mental health in Poplarville
- Ashley KarelVicksburg$129K
- Amanda HamCorinth$64K
- Alanna WrightJackson$58K
- Amanda ThomasTupelo$41K
- Amelia KelleyMeridian$38K
- Belinda EdwardsJackson$29K
- Lawanda GlassCleveland$22K
- Rebecca HartzogHattiesburg$17K
- Leigh CalcoteHattiesburg$15K
- Rose CliffordGautier$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.